{"denoms":[{"counts":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"147"},{"groupId":"BG003","value":"443"}],"units":"Participants"}],"groups":[{"description":"Participants apply a low dose (3.25 mg) of vaginal prasterone (dehydroepiandrosterone \\[DHEA\\]) gel once daily (QD), at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.","id":"BG000","title":"Arm I Low Dose DHEA"},{"description":"Participants apply a high dose (6.5 mg) of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.","id":"BG001","title":"Arm II High Dose DHEA"},{"description":"Participants apply a vaginal placebo gel QD, at bed time, for 12 weeks. \\>\n\n\\> There is an Optional Continuation Phase (for placebo arm only): Participants apply a high dose of vaginal DHEA gel QD, at bed time, for 12 weeks. Treatment continues until unacceptable adverse events or patient refusal to continue participation on the study.","id":"BG002","title":"Arm III Placebo"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"6.7","value":"56.8"},{"groupId":"BG001","spread":"8.2","value":"57.3"},{"groupId":"BG002","spread":"7.3","value":"58"},{"groupId":"BG003","spread":"7.4","value":"57.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"147"},{"groupId":"BG003","value":"443"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"149"},{"groupId":"BG002","value":"147"},{"groupId":"BG003","value":"443"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"All patients that were randomized to treatment were included in baseline characteristics."}